NCT04306484 (FDOPA) is a clinical trial of FDOPA-TEP in Brain Tumor, sponsored by Centre Hospitalier Universitaire de Nīmes.

Who is sponsoring NCT04306484?

NCT04306484 is sponsored by Centre Hospitalier Universitaire de Nīmes.

What drugs are being tested in NCT04306484?

Interventions in NCT04306484: FDOPA-TEP.

What condition does NCT04306484 study?

NCT04306484 studies Brain Tumor.

Is NCT04306484 still recruiting?

NCT04306484 is currently completed. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT04306484: FDOPA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions

Completed Last updated 4 December 2025

What this trial tests

trial testing FDOPA-TEP in Brain Tumor in 74 participants. Completed in 31 December 2020.

Timeline

1 January 2020

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nīmes
Status	Completed
Study type	OBSERVATIONAL
Enrollment	74
Start date	1 January 2020
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across France

Drugs / interventions tested

FDOPA-TEP

Conditions studied

Brain Tumor — all drugs for Brain Tumor →

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

18 and older, any sex, with Brain Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: 3,4-dihydroxy-6-\[18F\]-fluoro-L-phenylalanine (FDOPA) positron emission tomography (PET) can identify well low and high grade brain tumors. However, increased FDOPA uptake has been reported in non-tumoral brain lesions. The aim was to analyse FDOPA-PET in patients with non-tumoral brain lesions and to compare them with patients with (low and high grade) brain tumors. Methods: retrospective analyse. Patients consecutively recruited with suspected primary brain tumor (based on clinical and MRI findings) referred for FDOPA-PET at Nimes university Hospital between June 2015 and June 2019. FDOPA-PET parameters (maximum and mean lesion standardized uptake values \[SUV\] and ratios comparing lesion with different background uptake SUV) and thresholds were analysed in search for those offering optimal discrimination between non-tumoral and tumoral lesions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

<sup>18</sup>F-FDOPA-PET in pseudotumoral brain lesions.
Renard D, Collombier L, Laurent-Chabalier S, Mura T, et al · · 2021 · cited 3× · PMID 33084938 · DOI 10.1007/s00415-020-10269-9

Verify or expand the search:

Other recruiting trials for Brain Tumor

Currently open trials in the same condition.

NCT07224503 — C-SMART vs BE Well for Patients With Brain Tumors · NA · recruiting
NCT07323966 — Feasibility of Mask-Free Radiotherapy for Brain Tumor Patients · NA · recruiting
NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting
NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting
NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

NCT07403474 — Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Ther · Phase 4 · not yet recruiting
NCT07455981 — Work Organization and Gambling Addiction · not yet recruiting
NCT07403500 — Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. · NA · not yet recruiting
NCT07342010 — Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT · Phase 4 · not yet recruiting
NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04306484 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04306484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing